Leucine-based motif and Clostridial neurotoxins

Details Leucine-based motif and Clostridial neurotoxins Leucine-based motif and Clostridial neurotoxins

2008-07-01

2008-07-01

Hayes, Robert C. (Department: 1649)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C424S239100

Reexamination Certificate

active

07393925

ABSTRACT:
Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5053005 (1991-10-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5721215 (1998-02-01), Aoki et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6903187 (2005-06-01), Steward et al.
patent: 2002/0127247 (2002-09-01), Steward et al.
patent: WO 96/39166 (1996-12-01), None
patent: WO 97/32599 (1997-09-01), None
patent: WO 00/05252 (2000-02-01), None
Rudinger, “Characteristics of the amino acids as components of a peptide hormone sequence,” 1976, Parson, Ed., Peptide Hormones, University Park Press, pp. 1-7.
Zhou et al, “Expression and purification of the light chain of botulinum neurotoxin A: A single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstruction with the heavy chain”, Biochemistry, vol. 34, No. 46, pp. 15175-15181, 1995.
Binz et al, J. Biol Chem 265:9153-9156 (1990).
Shin et al, “Phosphorylation-Dependent Down-Modulation . . . ” J. Biol Chem 266: 10658-10665 (1991).
Raciborska et al, “Retention of Cleaved Synaptosome-Associated . . . ” Can. J. Physiol 77:679-688 (1999).
Fernandez-Salas, E., et al.,Plasma membrane localization signals in the light chain of botulinum neurotoxin, Proceedings of the National Academy of Sciences of the United States of America, Mar. 2, 2004, vol. 101, No. 9, pp. 3208-3213.
Erdal et al, Arch. Pharmacol 351: 67-78 (1995).
Ragona et al, “Management of Parotid Sialocele . . . ”, The Laryngoscope 109:1344-1346 (1999).
Naumann et al, “Botulinum Toxin Type A in the Treatment . . . ”, Eur. J. Neurol, 6: S111-S115 (1999).
Keller et al, “Persistence of Botulinum Neurotoxin”, FEBS Lett. 456: 137-142 (1999).
Dietrich et al, “Regulation and Function of the CD3yDxxxLL Motif . . . ”, J. Cell. Biol 138: 271-281 (1997).
Geisler et al, “Leucine-Based Receptor Sorting Motifs . . . ”, J. Biol. Chem. 273:21316-21323 (1998).
Tan et al, A Leucine-Based Motif Mediates the Endocytosis . . . , J. Biol. Chem. 273: 17351-17360 (1998).
Liu et al, “Membrane Trafficking of Neurotransmitter . . . ”, Trends Cell. Biol. 9: 356-363 (1999).
Cai et al, “A Correlation Between Differential Structural Features and the Degree of Endopeptidase”, Biochemistry 40 (15): 4693-4702 (2001).
Minton, “Molecular genetics of Clostridial Neurotoxins”, Montecucco C. (Ed.) Clostridial Neurotoxins in the molecular pathogenesis of tetanus and botulism, 161-194 (1995).
Fernandez-Salas, E., et al., “Plasma membrane signals in the light chain of Butulinum neurotoxin”, slide presentation at USAMRDD, Jan. 2004.
Fernandez-Salas, E., et al., “Is the light chain subcellular localization an important factor in Botulinum toxin duration of action?”, Movement Disorders (2004) 19: S23-S34.
Schantz et al, “Properties and use of Botulinum toxin and other microbial neurotoxins in medicine”, Microbiological Reviews, vol. 56, No. 1, 80-89 (Mar. 1992).
Rudinger In , “Peptide Hormones”, ed. J.A. Parsons, “Characterizations of the amino acids as components of a peptide hormone sequence”, University Part Press, Baltimore, pp. 1-7, (1976).

Affiliated with

Also associated with

Rating

Leucine-based motif and Clostridial neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Leucine-based motif and Clostridial neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leucine-based motif and Clostridial neurotoxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2812407